Granted Patent B2

US 8,992,939 · App. 13/280,043 · Granted Mar 31, 2015

Inventors: Gale Smith (Gaithersburg, MD); Yingyun Wu (Clarksburg, MD); Michael Massare (Mount Airy, MD); Peter Pushko (Frederick, MD); Margret Nathan (Montgomery Village, MD); Thomas Kort (Germantown, MD); Robin Robinson (Dickerson, MD)

Assignee: Novavax, Inc.

A61K39/12C12Y302/01018C12N9/2402A61K2039/5258A61K2039/55505A61K2039/55555C12N2760/16134C07K2319/03C12N2710/14143C12N2760/16122C12N2760/16123C12N2760/16151C12N2760/16171C12N2760/16223C12N2770/20022C12N2770/20023C12N2770/20051C12N2800/22

Abstract

Claims (20)

1. A virus-like particle (VLP) comprising an influenza M1 protein and at least one of an influenza hemacelutinin (HA) protein and an influenza neuraminidase (NA) protein, wherein said M1 protein comprises the amino acid residues YKKL at the positions corresponding to positions 100-103 of SEQ ID NO: 49, wherein the VLP lacks a viral genome and is non-infectious.

2. The VLP of claim 1 , wherein said influenza M1 protein is derived from an avian influenza virus strain.

3. The VLP of claim 2 , wherein said avian influenza virus strain is A/Indonesia/5/05.

4. The VLP of claim 1 , wherein said VLP comprises HA and NA proteins.

5. The VLP of claim 4 , wherein said HA and NA proteins are derived from an avian influenza virus.

6. The VLP of claim 5 , wherein said avian influenza virus is H5N1.

7. The VLP of claim 5 , wherein said avian influenza virus is H9N2.

8. The VLP of claim 4 , wherein said HA and NA proteins are derived from a seasonal influenza virus.

9. The VLP of claim 8 , wherein said seasonal influenza virus is a type A influenza virus.

10. The VLP of claim 8 , wherein said seasonal influenza virus is a type B influenza virus.

11. The VLP of claim 4 , wherein said HA and/or NA exhibit hemagglutinin activity and/or neuraminidase activity, respectively.

12. The VLP of claim 1 , wherein said HA and/or NA are chimeric proteins.

13. The VLP of claim 12 , wherein said chimeric proteins comprise external domains of non-avian influenza HA and/or NA protein sequences fused to the transmembrane and/or cytoplasmic terminal domains of the avian HA and/or NA.

14. The VLP of claim 13 , wherein said non-avian influenza HA and/or NA are from influenza strain A/Wisconsin/67/2005 and said avian influenza HA and/or NA are from influenza strain A/Indonesia/5/05.

15. A method of increasing the efficiency of VLP production comprising expressing an influenza M1 protein in a host cell, wherein said M1 protein comprises the amino acid residues YKKL at the positions corresponding to positions 100-103 of SEQ ID NO: 49, wherein the VLP comprises the influenza M1 protein and at least one of an influenza hemagglutinin (HA) protein and an influenza neuraminidase (NA) protein, and wherein the VLP lacks a viral genome and is non-infectious.

16. The method of claim 15 , wherein said influenza M1 protein is derived from an avian influenza virus strain.

17. The method of claim 16 , wherein said avian influenza virus strain is A/Indonesia/5/05.

18. The method of claim 15 , wherein said VLP comprises an influenza hemagglutinin (HA) and a neuraminidase (NA) protein.

19. The method of claim 18 , wherein said HA and NA proteins are derived from a seasonal influenza virus.

20. A vaccine comprising the VLP of claim 1 .

Assignments (2)

Continuity (15)